Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Other financing activities: 2020-2025

Historic Other financing activities for InMed Pharmaceuticals (INM) over the last 6 years, with Jun 2025 value amounting to $883,978.

  • InMed Pharmaceuticals' Other financing activities fell 28.49% to $137,178 in Q3 2025 from the same period last year, while for Sep 2025 it was $418,064, marking a year-over-year decrease of 56.70%. This contributed to the annual value of $883,978 for FY2025, which is 57.25% up from last year.
  • According to the latest figures from FY2025, InMed Pharmaceuticals' Other financing activities is $883,978, which was up 57.25% from $562,151 recorded in FY2024.
  • In the past 5 years, InMed Pharmaceuticals' Other financing activities ranged from a high of $1.8 million in FY2022 and a low of $562,151 during FY2024.
  • Its 3-year average for Other financing activities is $921,970, with a median of $883,978 in 2025.
  • In the last 5 years, InMed Pharmaceuticals' Other financing activities surged by 5,119.82% in 2021 and then slumped by 57.41% in 2024.
  • InMed Pharmaceuticals' Other financing activities (Yearly) stood at $1.6 million in 2021, then rose by 10.32% to $1.8 million in 2022, then dropped by 26.05% to $1.3 million in 2023, then plummeted by 57.41% to $562,151 in 2024, then skyrocketed by 57.25% to $883,978 in 2025.